Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation
HENDERSON, Nev., Feb. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, announces its Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation (NASDAQ: HSKA) ("Heska"). The Nu.Q® test will be showcased this weekend in Las Vegas at the 2023 Western Veterinary Conference, one of the world's largest veterinary conferences.
Heska's Nu.Q® Canine Cancer Screen and Monitor Test will operate on Heska's proprietary Element i+® Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low cost, and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes.
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "This is a breakthrough moment for Volition: it is the first time the Nu.Q® platform is available outside of centralised laboratory testing. Our mission at Volition is to ensure that our Nucleosomics™ technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes. We are delighted to be working with Heska and their remarkable point-of-care technology to enable vets, pets, and pet families to benefit from our innovative technology. We are thrilled to advance towards full commercial launch and license payment milestones."
Kevin Wilson, Heska's Chief Executive Officer and President said, "We are pleased now to offer our transformative Nu.Q® Canine Cancer Screen and Monitor Test at the point-of-care, which we believe will revolutionize canine cancer patient management. Available now for pre-order, the screen and monitoring test will assist veterinarians to detect cancer early, in the clinic, in minutes, and for under $50, to support clinical decision-making during annual check-ups, regular wellness exams, healthcare interventions, treatment cycles, and remission. While we also offer this technology at the central reference lab, we believe the benefits of point-of-care cancer screening and monitoring are significant and will provide outsized benefits to veterinarians, nursing and technical teams, pets, and pet families."
"With this forthcoming launch, millions of pets will have access to critical cancer screening and monitoring in the clinic, to catch, treat and drive recovery from cancers earlier, for better healthcare outcomes and peace of mind. We believe that this innovation will be transformative to veterinarian healthcare as Heska begins to roll it out exclusively to the point-of-care, with our global commercial launch targeted for early in the second quarter of this year," concluded Mr. Wilson.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com
Note to editors:
- Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test March 29 2022
- Findings from a clinical study conducted by Volition and Professor Wilson-Robles and the team at Texas A&M University, peer-reviewed and published in August 2022, showed that:
- Volition's Nu.Q® Vet Cancer Screening Test detected 76% of systemic cancers ( including lymphoma, hemangiosarcoma, and histiocytic sarcoma) at 97% specificity versus control.
Heska Corporation (NASDAQ: HSKA) sells, manufactures, markets, and supports diagnostic and specialty products and solutions for veterinary practitioners. Heska's portfolio includes point-of-care diagnostic laboratory instruments and consumables including rapid assay diagnostic products; digital cytology services; point-of-care digital imaging diagnostic products; local and cloud-based data services; practice information management software ("PIMS") and related software and support; reference laboratory testing; allergy testing and immunotherapy; heartworm preventive products; and vaccines. Heska's primary focus is supporting companion animal veterinarians in providing care to their patients. Heska's business is composed of two operating and reportable segments: North America and International. North America consists of the United States, Canada and Mexico. International consists of geographies outside of North America, primarily in Germany, Italy, Spain, France, Switzerland, Australia and Malaysia. Heska's strategic focus on point-of-care diagnostic laboratory and imaging products is included in both segments. The North America segment also includes the contract manufacturing of vaccines and pharmaceutical products and a small veterinary laboratory, and the international segment includes PIMS business and veterinary laboratories. For more information, please visit www.heska.com.
Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at Volition's and Heska's website addresses are not incorporated by reference into this document and should not be considered part of this document. Such website addresses are included in this document as inactive textual references only.
Louise Batchelor/Debra Daglish, Volition, firstname.lastname@example.org +44 (0)7557 774620
Jon Aagaard, Heska, email@example.com +1 970-617-8399
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's estimated market opportunity, expectations related to the potential benefits under the License and Supply Agreement with Heska, including the timing and success of product launches, the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
Video - https://www.youtube.com/watch?v=sVc6kMCWkho
View original content to download multimedia:https://www.prnewswire.com/news-releases/volitions-nuq-vet-cancer-test-now-available-for-pre-order-at-the-point-of-care-through-heska-corporation-301748809.html
SOURCE VolitionRx Limited
Released February 16, 2023